About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
https://soho2018.org/
Session I: Chronic Myeloid Leukemia
Session II: Myelodysplastic Syndromes
Session III: Myeloproliferative Neoplasms
Session IV: Acute Lymphoblastic Leukemia
Session V: Acute Myeloid Leukemia
Plenary Sessions
Breakfast with the Expert
Session VI: Multiple Myeloma
Program of Events
Session VIII: Non-Hodgkin Lymphoma
Session IX: Chronic Lymphocytic Leukemia
Session X: Research Topics
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
B
CLL Next Generation Reversible BTK Inhibitor, For Overcoming Acquired Resistance to Irreversible BTK Inhibitors
By
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
FEATURING
Barbara Brandhuber
By
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
FEATURING
Barbara Brandhuber
277 views
November 5, 2018
Oral Abstract CLL 200: LOXO-305
0 Comments
Login to view comments.
Click here to Login
Featured Video
18:47
Treatment Considerations in CLL: Challenging Patient Cases
Treatment Considerations in R/R CLL - A Patient Case Study
Feat.
J. N. Allan
Featured Video
14:41
Sanofi
Efficacy and Safety of a Treatment Option for Adults with Multiple M…
Feat.
J. Mikhael
Session IX: Chronic Lymphocytic Leukemia
13:46
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
CLL State of the Art Update: Biology, Therapeutic Landscape, Infecti…
Feat.
F. Cymbalista
16:37
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Evolving Firstline Treatment for Patients with CLL
Feat.
N. Jain
15:20
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
DEBATE: The Chemoimmunotherapy Era in CLL is Over
Feat.
P. Thompson
14:11
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
DEBATE: Chemoimmunotherapy in CLL is Over? No
Feat.
B. Eichhorst
15:46
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Optimal Sequencing of Molecules in the Treatment in Chronic Lymphocy…
Feat.
A. Mato
07:53
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Risk of Infection with Ibrutinib in Patients with CLL: A Systematic …
Feat.
S. Ball
10:13
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
CLL Next Generation Reversible BTK Inhibitor, For Overcoming Acquire…
Feat.
B. Brandhuber
13:08
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
CLL Next Questions: Biology, MRD, Risk Stratification, New Molecules…
Feat.
F. Cymbalista